Philippe V. Klitzing

Partner

2023

Investor

2025

Investor

2024

Investor

2024

Investor

2024

Investor

2023

Associate

2021 - 2022

Portfolio: - Valispace (B2B SaaS, engineering software, exited 2024) - Proxyclick (B2B SaaS, PropTech, exited 2022) - Wizzcad (B2B SaaS, Construction Tech, merged with Finalcad 2024) - 36 Zero Vision (B2B SaaS, industrial quality control) - Silico.ai (B2B SaaS, Decision Intelligence, wind down) - How.fm (B2B SaaS, Compliance Software) - IPRally (B2B SaaS, Patent Search) - beWanted (B2B SaaS, HR Tech) - Flexciton (B2B SaaS, Semi Conductor Software)

Analyst

2019 - 2021

Strategy Consultant

2018 - 2019

CEPTON is a leading boutique strategy consultancy serving mid to large corporations in areas of strategy and organisation as well as financial investors for due diligences. Examples of projects include: - Strategic due diligence projects for private equity funds (i.e. aesthetics, analytical testing) - Streamlining of product portfolio for a pharma and dermo-cosmetic company - Market analysis of patient support & prevention programs in Germany for a leading HCP - Structuring and implementation of a strategic alliance project between two FinTechs - Optimisation of the international investment strategy for a large French pharma company

Co-founder & COO (sold)

2015 - 2017

Innovative, next generation storage company to take the pain out of using a traditional storage unit by offering a by-the-box service. - Winner of the Prix du Public of the Startup Academy 2015 - Runner-Up of the Moovjee 2016 Prize - Winner of the EnModeUp! Accelerator Program 2016 Acquisitions: Wesquare (2015), La Boite Qui Cartonne (2016), remaining activity from Boxon (2016) Commeunearmoire's activity was sold to Stocketmoi in November 2017.

Junior Analyst Venture Capital

2014 - 2014

Large Venture is a €1bn vehicle investing in high-growth innovative companies with significant capital requirements in the biotech & healthcare, digital, and green tech spaces. Large Venture invests in VC-backed companies (or validated by significant revenue traction) thus continuing and leveraging the financing started by early-stage investors. Played an active role in four minority investments: - Poxel (€10m): drug development for Type 2 diabetes (spin-off from Merck) - TxCell (€8m): autologous cellular therapies for patients suffering from Crohn's disease - Pixium Vision (€15m): Intelligent retinal implant device that aims to recover a near normal vision for people who lost their sight due to degenerative disorders of the eye - DBV Technologies (€15m): innovative solutions in the field of food and pediatric allergies